Drug intelligence / Profile preview

SPX-102

Development stage: Unknown
Lead developer: SPARX THERAPEUTICS
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SPX-102 is a humanized monoclonal antibody developed by **SparX Biotech** that targets the **Human Epidermal Growth Factor Receptor 2 (HER2)**. Developed using the company's proprietary SAILING™ platform, SPX-102 is designed to treat HER2-positive solid tumors by binding to the HER2 receptor and inhibiting downstream signaling pathways that drive tumor growth and proliferation. It may also facilitate antibody-dependent cellular cytotoxicity (ADCC) to enhance anti-tumor activity. The drug is currently in early-stage clinical development, positioned within SparX's oncology pipeline alongside other HER-family targeted agents and bispecific antibodies.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on SPX-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPX-102.

Explore the full profile